31 results about "Bacteroides fragilis" patented technology

The application provides application of Bacteroides fragilis in improving and / or treating diarrhea. It is proved by different mouse diarrhea model tests that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No. 10685 or inactivated bacteria thereof have the effects of improving and treating diarrhea. The inactivated bacteria powder of the Bacteroides fragilis has better effects on improving infectious diarrhea or non-infectious diarrhea under different concentration formulations, has no side effects on the body, has a good edible and application prospect, and provides a good product suitable for human consumption for health care and improvement of diarrhea.

The invention discloses an osthole derivative shown in a general formula 3 in the technical field of organic chemistry. The substituent group R of # imgabs0 is nitroimidazole, substituted nitroimidazole, nitrobenzimidazole or nitrotriazole; and n is 3 or 4. The invention further relates to application of the compound shown in the general formula 3 to preparation of antibacterial drugs independently or in combination with antibacterial active ingredients, and bacteria comprise any one of bacteroides fragilis, anaerobic peptostreptococcus, staphylococcus aureus and escherichia coli.

Provided are methods for producing polysaccharides in bacteria by expressing in a bacterium one or more coding sequences selected from the group consisting of a pglF dehydrogenase coding sequence, a wbpP UDP-N-acetyl-d-glucosamine C4 epimerase coding sequence, a wcfR aminotransferase coding sequence, and a wcfS phospho-glycosyltransferase coding sequence, a wcfQ glycosyltransferase coding sequence, a wcfO pyruvyltransferase coding sequence, a wcfP glycosyltransferase coding sequence, a wcfM UDP-galactopyranose mutase coding sequence, a wcfN glycosyltransferase coding sequence, a wza polysaccharide export protein coding sequence, a wzx fippase coding sequence, a wzy polymerase coding sequence, and a wzz coding sequence, wherein at least one of the coding sequences is heterologous to the bacterium. Also provided are expression cassettes with one or more of the disclosed coding sequences, recombinant bacteria that harbor one or more of the expression cassettes, and methods for producing immunogenic compositions using the polysaccharides produced by the recombinant bacteria.

The invention provides application of bacteroides fragilis 839 in preparation of health food, food composition or medicine for improving hepatotoxicity caused by antituberculosis medicine. The bacteroides fragilis BF839 is adopted for the first time in the world to improve the mouse hepatotoxicity caused by the antituberculous drug, and it is found that the bacteroides fragilis BF839 can reduce or relieve the mouse hepatotoxicity caused by the antituberculous drug and has the advantages of being efficient and safe.

The invention provides an osteoporosis diagnostic marker composition and application thereof in preparation of an osteoporosis diagnostic product, and relates to the technical field of biology. According to the invention, the osteoporosis diagnostic marker composition comprising at least one of Kotill campylobacter, Lactobacillus fragilis, Streptococcus parahaemolyticus, Porphyromonas sp and Bacteroides fragilis is applied to the preparation of the osteoporosis diagnostic product, so that the breakthrough on the traditional detection means dependent on bone mineral density is realized; and a molecular-level, early-stage and non-invasive risk early warning means is provided.

A microorganism containing Bacteroides fragilis genes is used as an active ingredient in the preparation of pharmaceuticals, medical devices, or food for treating optic nerve damage. This delivers Bacteroides fragilis (or its functional components) into the gastrointestinal tract, which helps maintain the number of retinal ganglion cells and the thickness of the retinal nerve fiber layer, inhibits the activation of retinal microglia, inhibits the activation of retinal inflammatory pathways and the expression of inflammatory mediators, thereby protecting visual function.

The microorganism contains the bacteroides fragilis gene, and the bacteroides fragilis gene is used as an active ingredient to be applied to preparation of medicine or food for treating optic nerve damage, the bacteroides fragilis (or functional components thereof) is delivered to gastrointestinal tracts, the number of retinal ganglion cells and the thickness of a retinal nerve fiber layer can be maintained, activation of retinal microglia cells is inhibited, and optic nerve damage is inhibited. Retina inflammation pathway activation and inflammatory mediator expression are inhibited, so that the visual function is protected.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

This invention discloses novel specific molecular targets for *Bacteroides fragilis* and its BFS17, along with a rapid detection method. The molecular target nucleotide sequence of *Bacteroides fragilis* is shown in SEQ ID NO.1, and the molecular target nucleotide sequence of *Bacteroides fragilis* BFS17 is shown in SEQ ID NO.2. This invention uses a pan-genomic approach to obtain the specific core genes of *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17, and designs characteristic primers that can sensitively detect *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17. Furthermore, this method can rapidly and easily distinguish *Bacteroides fragilis*, the probiotic strain *Bacteroides fragilis* BFS17, and other microbial strains. This invention has the advantages of being simple and rapid to operate, highly specific, quantifiable, and inexpensive.

The invention discloses application of alpha-caryophyllene in preparation of a medicine for treating colorectal cancer. The alpha-caryophyllene can regulate the abundance of bacteroides fragilis capable of producing enterotoxin, inhibit the proliferation and migration ability of colorectal tumor cells mediated by bacteroides fragilis capable of producing enterotoxin, and can slow down the progress of colon cancer by improving the abundance of intestinal microorganisms. The invention discloses a new application of alpha-caryophyllene in preparation of medicines for treating colorectal cancer, and provides a new application direction. Alpha-caryophyllene is a natural active component, has low side effects and is easily accepted clinically. The invention provides new scientific research evidence for research and development of medicines for treating colorectal cancer, and has important clinical application value and development value.

The invention belongs to the technical field of biology, and particularly relates to a fucosyltransferase mutant and application thereof. According to the invention, a plurality of mutation sites of alpha-1, 2-fucosyltransferase (wcfB) of Bacteroides fragilis are obtained through bioinformatics analysis and mining, mutants are constructed through point mutation and combinatorial mutation, and the ability of the mutants to catalytically produce 2 '-FL is verified in Escherichia coli Nissle 1917. According to the alpha-1, 2-fucosyltransferase mutant obtained through screening, the yield of 2 '-FL is increased by 20% or above compared with the yield of a wild original recombinant strain, and the yield of the highest M51 is increased by 93.1%. The transformation strategies provided by the invention provide important theoretical and technical support for the alpha-1, 2-fucosyltransferase in the industrial production of breast milk oligosaccharides such as 2 '-FL and the like.

Described herein are compositions, methods, and kits for detecting wound pathogens. One embodiment described herein is primer pairs and probes for individual, simultaneous, or sequential multiplex polymerase chain reaction (PCR) based assays for the detection of Acinetobacter baumannii, Bacteroides fragilis, Clostridium perfringens, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Klebsiella aerogenes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus anginosus, Staphylococcus lugdunensis, Providencia stuartii, Stenotrophomonas maltophilia, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Citrobacter braakii, Peptoniphilus asaccharolyticus, Peptoniphilus harei, Peptoniphilus ivorii, Peptostreptococcus anaerobius, Finegoldia magna, Clostridium septicum, Paeniclostridium sordellii (Clostridium sordellii), Clostridium novyi A, B, Clostridium histolyticum, Staphylococcus epidermidis, Staphylococcus haemolyticus, Corynebacterium striatum, Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, or Candida tropicalis.

The invention belongs to the technical field of microbial genetic engineering and protein delivery, and particularly relates to an engineered bacterial secretion system for efficiently delivering protein and application of the engineered bacterial secretion system. Specifically, on the basis of analyzing a delivery mechanism of bacteroides fragilis GS086 type double-effect protein T6SS, engineering modification is performed on a toxic structural domain of the effect protein, and a bacterial secretion system capable of efficiently and simultaneously delivering a plurality of proteins is constructed. According to the system, a modified strain is a natural human intestinal symbiotic bacterium, the problems of high immunogenicity, poor stability and the like are effectively avoided, and protein can be delivered in situ in the intestinal tract to realize precise regulation and control of an intestinal flora structure and secretion of specific target protein, so that the system has a good practical application value.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

The invention relates to the technical field of microorganisms, in particular to application of Bacteroides fragilis in preparation of a product for preventing or treating chicken testis blood testis barrier injury. The invention discloses application of Bacteroides fragilis in preparation of products for preventing or treating chicken testis blood-testis barrier injury for the first time, and experiments prove that the Bacteroides fragilis can improve the weight of chicken testis, the diameter and area of the testis, the number of spermatogonial stem cells in the testis and the expression level of testis blood-testis barrier related protein, and can be used for preparing a product for preventing or treating chicken testis blood-testis barrier injury. The completeness and functions of chicken testis cells can be maintained, and the normal development of the testis can be promoted. The application of the Bacteroides fragilis in the field of reproductive development of chickens is beneficial for promoting the breeding industry to develop towards a more efficient and sustainable direction.

The invention belongs to the technical field of polysaccharide vaccine vector synthesis, and relates to a pentasaccharide repeating unit and decasaccharide repeating unit compound of zwitterionic polysaccharide PS A2 and a synthesis method thereof. The PS A2 pentasaccharide repeating unit is successfully synthesized through a [2 + 2 + 1] strategy, and the technical problems of construction of a mannoheptaose C6-position ether bond, determination of a side chain methyl configuration, efficient construction of a 1, 2-cis-glucosidic bond, synthesis of multiple amino sugars and the like in the synthesis process are solved. The pentasaccharide repeating unit is coupled with other compounds and can be used for researching the potential anticancer effect of the PS A2. The pentasaccharide repeating units with different chiral methyl groups on the side chains provided by the invention can be used for subsequently performing activity screening on the two pentasaccharide repeating units to compare the influence of different methyl chirality on antigenicity, so that a foundation is laid for bacteroides fragilis sugar vaccines; the decasaccharide repeating unit provided by the invention provides a new path for synthesizing long-chain zwitterionic polysaccharide PS A2.

The invention relates to the technical field of biology, in particular to bacteroides fragilis FMBL Ba24006 DMX for metabolism of pectic polysaccharides and application, the bacteroides fragilis FMBL Ba24006 DMX is preserved in China Center for Type Culture Collection on January 20, 2026, the preservation number is CCTCC M 2026175, the bacteroides fragilis FMBL Ba24006 DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and meanwhile, the bacteroides fragilis FMBL Ba24006 DMX can be used for metabolism of pectic polysaccharides. The bacterial strain has a good antibacterial effect on hemorrhagic Escherichia coli; the compound is sensitive and moderately sensitive to cefoxitin and rifampicin. The strain can produce a large amount of short-chain fatty acid when being used for fermenting pectin, and fermentation liquor taking the pectin as a carbon source has relatively strong scavenging capacity on DPPH and ABTS free radicals; a relatively good inhibition effect is achieved on the activity of alpha-amylase; the method can be used for preparing antioxidant products, fermented foods, health-care products, food additives and feeds, and has a wide application prospect.

The invention discloses a composition, a kit and a detection method for detecting bacterial infection pathogens. The composition comprises at least one of a component A, a component B and a component C, the component A comprises nucleotide sequences as shown in SEQ ID NO: 1-3, and the component A is used for detecting bacteroides fragilis; the component B comprises nucleotide sequences as shown in SEQ ID NO: 4-6, and the component B is used for detecting citrobacter freundii; the component C comprises nucleotide sequences as shown in SEQ ID NO: 7-9, and the component C is used for detecting enterobacter aerogenes. By designing the upstream and downstream primers and the corresponding probes, the composition for detecting the bacterial infection pathogens can detect and distinguish at least one of bacteroides fragilis, citrobacter freundii and enterobacter aerogenes, is high in sensitivity, high in specificity and strong in anti-interference performance, improves the detection efficiency, shortens the detection period, reduces the detection cost, and is suitable for popularization and application. Good application prospects are realized.

The invention belongs to the technical field of disease prognosis and molecular biology, and relates to a flora marker for colorectal cancer liver metastasis diagnosis and liver metastasis risk assessment and application of the flora marker. The marker comprises the following three strains: bifidobacterium bifidum, bacteroides fragilis and bacteroides heparinidolyticus. The method comprises the following steps: acquiring information of microorganisms in excrement of a patient through a high-resolution metagenomics detection technology; a random forest algorithm is utilized to construct a colorectal cancer liver metastasis classification model based on the flora markers, the model can distinguish people without colorectal cancer metastasis and people with liver metastasis and accurately predict high-risk patients with colorectal cancer liver metastasis, and the effect of the model is superior to that of a clinical conventional tumor serum marker. The kit has the advantages of noninvasive detection and high accuracy, and can provide a reliable tool for liver metastasis diagnosis and individualized prognosis management of colorectal cancer patients.

Provided in the present application are a real-time quantitative detection method for next-generation probiotics on the basis of flow cytometry and the use thereof. The next-generation probiotics comprise Akkermansia muciniphila and / or Bacteroides fragilis. In the present application, flow cytometry is used in the detection of next-generation probiotics to provide quantitative data of viable and non-viable cells in real time, thereby rapidly completing the high-throughput detection of viable cells in a sample while reducing the risk of contamination during the detection process. Moreover, the detection method can also detect next-generation probiotics that are unculturable due to insufficient metabolic activity, offering rapid detection speed and high accuracy.

The invention discloses application of bacteroides fragilis in preparation of a medicine for preventing and / or treating porcine intestinal coronavirus infection. The research finds that bacteroides fragilis hydrolyzes bound bile acid through bile salt hydrolase (BSH) to generate free bile acid (such as lithocholic acid LCA and deoxycholic acid DCA), so that an antiviral effect is generated. The bacteroides fragilis can regulate bile acid metabolism through BSH enzyme activity to inhibit virus infection, which indicates that the bacteroides fragilis can be used for preventing or treating porcine intestinal coronavirus infection.

The invention provides bacteroides fragilis capable of relieving enteritis and application of the bacteroides fragilis, and belongs to the technical field of microorganisms. The Bacteroides fragilis is Bacteroides fragilis NJ, the preservation number of the Bacteroides fragilis NJ in the China General Microbiological Culture Collection Center is CGMCC No.46606, and the Bacteroides fragilis NJ has the effects of inhibiting colonization of pathogenic enterobacteria, relieving host colon tissue lesions and intestinal inflammation, effectively reducing the level of inflammatory cytokines such as TNF-alpha and IL-17 in serum, and improving the immunogenicity of the serum. The abundance of enterotoxin-producing bacteroides fragilis in intestinal tracts is reduced; and a new way and method can be provided for prevention and treatment of intestinal inflammation.

The present application relates to a strain of Bacteroides fragilis and its application, the strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 14, 2026, and the preservation number is: CGMCC No. 38257.The strain can regulate STING-dependent training immunity, effectively resist Salmonella typhimurium and H9N2 avian influenza virus infection, maintain the integrity of the intestinal barrier of the host, and reduce inflammatory damage.The Bacteroides fragilis of the present application has good biological safety, and the strain can be used as a training immunity inducer, and the strain is expected to be a candidate probiotic or vaccine adjuvant for preventing / treating bacterial and viral infections, suitable for human health and poultry farming, and provides a new solution to resist antibiotic resistance.

The invention discloses a recombinase combination suitable for bacteroides, application and a homologous recombination method, and belongs to the technical field of microbial genetic engineering. The invention discloses a method for constructing and screening a combination of a single-chain annealing protein and a single-chain binding protein for the first time. A single-chain annealing protein and a single-chain binding protein are jointly constructed in an escherichia coli-bacteroides fragilis shuttle expression vector, and co-expression of the escherichia coli-bacteroides fragilis shuttle expression vector in bacteroides fragilis is achieved, so that the homologous recombination capacity of bacteroides fragilis is remarkably improved. According to the method disclosed by the invention, the homologous recombination efficiency of genome editing of bacteroides fragilis is greatly improved, the absolute editing efficiency of the genome is improved to 0.052% from the original level which is almost undetectable, and the research and application progress of genome engineering of the strain is remarkably promoted.

The invention relates to the technical field of functional microorganism application, and particularly provides a synbiotics preparation with a function of relieving type 2 diabetes and application of the synbiotics preparation. According to the synbiotics preparation provided by the invention, through the synergistic effect of the three probiotics of bacteroides fragilis, bifidobacterium animalis subsp. Lactis and phytobacterium plantarum and the prebiotics, the blood lipid metabolism disorder of mice with the type 2 diabetes mellitus can be effectively regulated, the level of TNF-alpha and IL-6 inflammatory factors in serum of the mice is remarkably reduced, and the synbiotics preparation has the effect of relieving the type 2 diabetes mellitus.

The application discloses application of Bacteroides fragilis in preparation of products for preventing and / or treating celiac disease, and a composition containing Bacteroides fragilis for treating and / or preventing celiac disease. The application proves through a large number of experiments that Bacteroides fragilis, especially Bacteroides fragilis ZY-312 with a preservation number of CGMCC No. 10685, can increase the expression of tight junction related proteins, improve intestinal barrier permeability, down-regulate TTG-IgA antibodies and pro-inflammatory factors IFN gamma and IL-15, reduce inflammation, and effectively prevent and treat celiac disease.

The invention relates to the technical field of biological medicines, and particularly discloses a preparation method and application of a composition of probiotics and essential amino acids for optimizing a hepatitis B virus infection immune microenvironment. According to the scheme, the composition formed by combining bacteroides fragilis DSM 2151 and branched chain amino acids can promote serum HBsAg removal, and the removal rate is high; according to the present invention, the serum HBsAg removal promoting effect of the probiotic Bacteroides fragilis DSM 2151 and the branched chain amino acid composition is superior to the serum HBsAg removal promoting effect of the probiotic Bacteroides fragilis DSM 2151 single use and the branched chain amino acid single use, the test results prove that the serum HBsAg negative conversion rate of the Bacteroides fragilis DSM 2151 group in the mouse hepatitis B model is about 66.67%, the serum HBsAg negative conversion rate of the branched chain amino acid group in the mouse hepatitis B model is 35.71%, and the negative conversion rates of the Bacteroides fragilis DSM 2151 and the branched chain amino acid composition group are respectively 26.19% and 57.15% higher; in addition, the hepatitis B liver immune microenvironment can be improved, and tests prove that the average value of the proportion of effector CD8 + T and effector CD4 + T cells is two times higher than that of a PBS control group; in addition, the invention can improve the level of effector IFN-gamma in serum of hepatitis B mice.

The present invention relates to the use of Bacteroides fragilis in the preparation of a medicament for preventing and treating irritable bowel syndrome. The present invention confirms through in vivo experiments that Bacteroides fragilis ZY-312 has therapeutic and preventive effects on diarrhea-predominant irritable bowel syndrome.

The invention discloses a novel non-enterotoxin-producing bacteroides fragilis strain with a colorectal cancer inhibiting effect, belongs to the field of microorganisms, and is named as ZY0804, and the preservation number is CGMCC No.33783. The invention further discloses a preparation method of the novel non-enterotoxin-producing bacteroides fragilis strain. Experimental research proves that the novel NTBF derived from the para-carcinoma tissue of the CRC patient plays a remarkable role in inhibiting the development process of the colorectal cancer. Good application and medicine research values are realized.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.